Published in Vaccine Weekly, October 16th, 2002
"In this study, we characterized molecular components that are required to produce immune responses that eliminate Panc02.MUC1 tumors in vivo by utilizing mice genetically deficient in molecules related to immunity," reported Connie L. Sivinski and colleagues at the University of Nebraska Medical Center in Omaha.
The investigators found that CD8+ effector cells were necessary to destroy Panc02 tumors that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.